SelektaDx™ Diagnostic Platform: A Rapid Multiplex Molecular Detection of Mycobacterium tuberculosis Complex and its Key Drug Resistance
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Nikhil Sangith1,2,3, Manju Purohit4,5, Vasim Ahmad6, Narayanan Madaboosi7, Cecilia Stålsby Lundborg5, Pavan Asalapuram1,2,3,5 1Research and Development Unit, Mitti Lifetek AB, 5Department of Global Public Health, Karolinska Institute, Stockholm, Sweden, 2Xact Diagnotek Private Limited, TNAU Campus, 3Tamil Nadu Agricultural University, Coimbatore, 7Department of Medical Sciences and Technology, Indian Institute of Technology - Madras, Chennai, Tamil Nadu, 4Department of Pathology, R. D. Gardi Medical College, Ujjain, Madhya Pradesh, 6Department of Microbiology, Culture and DST Laboratory, Rajan Babu Institute of Pulmonary Medicine, New Delhi, India Address for correspondence: Dr. Pavan Asalapuram, Research and Development Unit, Mitti Lifetek AB, Stockholm, Sweden. E-mail: [email protected] Background: The rise of multidrug-resistant tuberculosis (MDR-TB) continues to pose a major challenge to global TB control. World Health Organization (WHO)-recommended shorter all-oral regimens, such as the 6-month bedaquiline, pretomanid, linezolid, and moxifloxacin regimen (BPaLM), have demonstrated high treatment success rates (>90% in clinical trials) for rifampicin-resistant TB. However, effective implementation of these regimens critically depends on rapid and reliable diagnostics that can simultaneously confirm TB and detect resistance to both first-line drugs (rifampicin and isoniazid) and key second-line drugs (fluoroquinolones and bedaquiline), which directly determine regimen eligibility. While molecular diagnostics such as GeneXpert, Truenat, and line probe assays enable decentralized detection of rifampicin, isoniazid, and fluoroquinolone resistance, substantial gaps remain in decentralized detection of bedaquiline resistance and in comprehensive confirmation of MDR-TB in resource-limited settings. Phenotypic drug susceptibility testing for these agents often requires weeks, specialized biosafety infrastructure, and centralized laboratories, delaying personalized treatment and increasing the risk of resistance amplification and transmission. Methods: To address these diagnostic gaps, we developed the SelektaDx™ MDR-TB test, a modified intercepting multiplex real-time polymerase chain reaction (PCR) assay incorporating a dual-layer detection architecture. The assay integrates MutaSelect™ probes for mutation-selective amplification of clinically relevant resistance markers with FluoroSelect™ probes for highly sensitive amplicon detection. This design enables concurrent identification of the Mycobacterium tuberculosis complex and resistance determinants spanning first-line (rifampicin and isoniazid) and second-line (fluoroquinolones and bedaquiline) drugs directly from sputum samples. The test delivers results within approximately 90 min using standard real-time PCR instruments and basic diagnostic laboratory infrastructure, supporting decentralized deployment in low- and middle-income countries. Results: In a pilot clinical evaluation of 50 sputum samples, the SelektaDx™ MDR-TB test demonstrated 99% sensitivity and 100% specificity for TB detection and rifampicin/isoniazid resistance when benchmarked against GeneXpert and mycobacteria growth indicator tube culture-based methods. Analytical validation using precharacterized MDR-TB specimens confirmed robust assay performance and reproducibility. A larger prospective clinical evaluation is currently underway in India, enrolling 300 MDR-TB samples, with a specific focus on detecting resistance to rifampicin, isoniazid, fluoroquinolones, and bedaquiline. This evaluation aims to directly inform regimen selection, including eligibility for BPaLM-based therapy, and to strengthen antimicrobial stewardship by enabling earlier, evidence-based treatment decisions. Conclusions: SelektaDx™ represents a rapid, modular, and cost-effective molecular diagnostic platform that integrates confirmation of TB with clinically actionable resistance detection across both first-line and critical second-line drugs. By enabling early, decentralized identification of MDR-TB and resistance patterns relevant to modern all-oral regimens, the platform supports timely personalized treatment, reduces diagnostic delays, limits resistance amplification, and advances the implementation of WHO-recommended care pathways in alignment with the end TB strategy and the United Nations Sustainable Development Goals. Keywords: Bedaquiline, pretomanid, linezolid, and moxifloxacin, molecular diagnostics, multidrug-resistant tuberculosis Conflicts of interest There are no conflicts of interest
Fields of Study & Subjects
Tuberculosis Research and Epidemiology
Infectious Diseases and Tuberculosis
Mycobacterium research and diagnosis
Publication details
- Journal / source
- International Journal of Mycobacteriology
- Volume
- 15
- Issue
- Abstract Supplement
- Pages
- S8–S8
- Publication date
- 1 March 2026
- Language
- EN